A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration
← catalyst calendarNCT06970665 · readout in 315 d
Sponsored by Astellas Pharma Inc (industry) · 4503.T — their whole pipeline →.
Phase
Phase 4
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
17actual
Sites
16
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-08 | actual | When the study began enrolling |
| Primary completion | 2027-06-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-06-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Geographic Atrophy
- Age-Related Macular Degeneration
Intervention
- Drug: avacincaptad pegol — also filed as ASP3021, IZERVAY
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with Treatment Emergent Adverse Events (TEAEs)
measured Up to 12 Months
Number of participants with Serious TEAEs
measured Up to 12 Months
Permalink · 4503.T's whole pipeline · Catalyst calendar · Every registered study · What changed